Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (symbol: NLTX) is a cutting-edge biopharmaceutical company focused on the development of next-generation immunotherapies. Using advanced de novo protein design technology, Neoleukin creates synthetic proteins with specific pharmaceutical properties designed to treat cancer, inflammation, and autoimmune diseases.
In recent developments, Neoleukin has implemented a reverse stock split, approved by its stockholders at the 2023 Annual Meeting held on June 8, 2023, and executed by the Board on August 30, 2023. This reverse stock split reduces the number of shares of common stock from approximately 44,026,429 to about 8,805,285, while also adjusting the number of authorized shares from 100,000,000 to 20,000,000. While this adjustment affects all stockholders uniformly, it simplifies stock management without altering any stockholder’s ownership percentage, except for those receiving cash in lieu of fractional shares.
As of March 2023, Neoleukin restructured its operations to conserve capital. This strategic move was part of an overarching plan to streamline operations while focusing on its core competencies. The company continues to leverage its sophisticated computational methods to develop proteins with superior therapeutic benefits compared to native proteins. Neoleukin's innovation has positioned it as a leader in the biotechnology sector, providing advanced solutions for complex health challenges.
Furthermore, a proposed merger and its anticipated impacts on the company’s stock and listing on the Nasdaq Capital Market are key topics for investors. The merger is expected to result in a combined total of approximately 13,676,732 shares of outstanding common stock.
For more information, please visit the Neoleukin website or contact Neoleukin's investor relations and media teams at investors@neoleukin.com.
Neoleukin Therapeutics (NASDAQ:NLTX) announced the initiation of a combination arm in their Phase 1 trial assessing NL-201 alongside Merck's KEYTRUDA® for patients with relapsed or refractory solid tumors. This phase aims to evaluate safety, pharmacokinetics, and antitumor activity in up to 132 patients. The trial follows encouraging preclinical data indicating the potential for enhanced patient outcomes. NL-201, designed to activate CD8 T and NK cells, aims to improve tolerability and effectiveness, advancing Neoleukin's innovative approach to cancer treatment.
Neoleukin Therapeutics (NASDAQ: NLTX) reported financial results for Q1 2022, with cash reserves of $128.1 million, down from $142.5 million at the end of 2021. R&D expenses rose to $10.7 million, driven by clinical trial costs for NL-201, while G&A expenses decreased to $4.7 million. The net loss widened to $15.4 million, compared to $14.9 million in Q1 2021. Neoleukin is advancing its NL-201 clinical trial for solid tumors, with interim data expected in H2 2022. A separate trial for hematologic malignancies will follow based on current trial results.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in two investor conferences. The first is the BofA Securities 2022 Healthcare Conference in Las Vegas on May 11, 2022, featuring a fireside chat at 1:20 p.m. Pacific. The second event is the H.C. Wainwright Global Investment Conference in Miami on May 25, 2022, where Drachman will present at 12:30 p.m. Eastern. Webcasts for both presentations will be available on the Neoleukin investor website, with archived replays accessible for 30 days.
Neoleukin Therapeutics (NASDAQ: NLTX) announced promising preclinical results for its immunotherapy candidate NL-201, demonstrating significant antitumor activity against B-cell lymphoma models. The data highlights NL-201's ability to synergize with radiation therapy, promoting robust immune responses and enhancing survival rates in murine models. A first-in-human Phase 1 trial is actively enrolling patients to assess NL-201's safety and recommended dosage. These findings indicate NL-201's potential across various cancer types and support further clinical investigations.
On April 7, 2022, Neoleukin Therapeutics (NASDAQ:NLTX) announced that its CEO, Jonathan Drachman, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 12:00 p.m. Eastern. The event will be accessible via a webcast on Neoleukin's website, with an archived replay available for 30 days post-event. Neoleukin is focusing on developing next-generation immunotherapies for cancer and autoimmune conditions through advanced protein design technology, notably its lead candidate, NL-201.
Neoleukin Therapeutics (NASDAQ:NLTX) has appointed Donna M. Cochener as its new General Counsel and Senior Vice President of Legal. Cochener brings extensive experience in public company practices and securities law from her previous role at HomeStreet, Inc., where she oversaw securities reporting and compliance. She expressed enthusiasm for joining Neoleukin, emphasizing its mission to develop new therapies for life-threatening diseases. Neoleukin focuses on designing innovative protein therapeutics for cancer and autoimmune conditions.
Neoleukin Therapeutics (NASDAQ: NLTX) announced three significant presentations at the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The presentations highlight preclinical data demonstrating the efficacy of NL-201, a novel protein therapeutic, in treating hematologic cancers and its potential synergy with radiation therapy. Key findings suggest NL-201's ability to enhance antitumor immunity across various cancer indications. The sessions will showcase the compound’s antitumor activity in B cell lymphoma models and details from a first-in-human Phase 1 study.
Neoleukin Therapeutics (NASDAQ:NLTX) has reported its 2021 financial results, highlighting a cash position of $142.5 million, sufficient to fund operations into the second half of 2023. The company is advancing its clinical trial for NL-201, with interim data anticipated in the latter half of 2022. R&D expenses rose to $39.2 million in 2021, largely due to clinical activities. The net loss increased to $60.7 million, up from $33.3 million in 2020. Additionally, Rohan Palekar has joined the Board of Directors, enhancing strategic expertise.
Neoleukin Therapeutics (NASDAQ:NLTX) has announced it will report its full year 2021 financial results on March 1, 2022. The company will host a conference call at 1:30 p.m. Pacific to discuss the results and provide a corporate update. Neoleukin focuses on designing de novo protein therapeutics for cancer and autoimmune diseases. Its lead candidate, NL-201, targets improved tolerability and efficacy compared to native proteins. Archived audio of the call will be available for replay on their investor relations website.
Neoleukin Therapeutics (NASDAQ:NLTX) has announced that CEO Jonathan Drachman, M.D., will participate in a fireside chat at the Guggenheim Healthcare Oncology Talks 2022 Conference on February 10, 2022, at 1:30 p.m. Eastern. The event will be accessible via a webcast on the company's investor website, with an archived replay available for 30 days post-event. Neoleukin specializes in creating next-generation immunotherapies using advanced computational methods for protein design, focusing on innovative treatments for cancer, inflammation, and autoimmunity.
FAQ
What is the market cap of Neoleukin Therapeutics (NLTX)?
What does Neoleukin Therapeutics, Inc. do?
What is the recent reverse stock split about?
How does the reverse stock split affect stockholders?
Why did Neoleukin restructure its operations?
What are the notable technologies used by Neoleukin?
What is the impact of the proposed merger on Neoleukin's stock?
How can investors contact Neoleukin Therapeutics?
What is the significance of the de novo protein design technology?
Does the reverse stock split affect the company’s Nasdaq listing?
Where can I find more information about Neoleukin's recent developments?
